Shares of Trovagene Inc. (NASDAQ:TROV) traded down 3.5% during mid-day trading on Thursday . The company traded as low as $5.39 and last traded at $5.49, with a volume of 401,748 shares trading hands. The stock had previously closed at $5.69.

A number of analysts have issued reports on the stock. Leerink Swann reiterated a “hold” rating on shares of Trovagene in a research note on Thursday, May 12th. Cantor Fitzgerald reissued a “hold” rating and issued a $5.00 price target on shares of Trovagene in a research report on Wednesday, May 11th. Argus lowered shares of Trovagene from a “buy” rating to a “hold” rating in a research report on Thursday, April 28th. Piper Jaffray Cos. lowered shares of Trovagene from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $5.26 to $8.00 in a research report on Monday, April 25th. Finally, Zacks Investment Research raised shares of Trovagene from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $6.96.

The company’s market cap is $162.74 million. The stock has a 50-day moving average price of $4.78 and a 200 day moving average price of $4.78.

Trovagene (NASDAQ:TROV) last posted its earnings results on Tuesday, May 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.07. On average, equities research analysts expect that Trovagene Inc. will post ($1.26) EPS for the current fiscal year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.